{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:29Z","timestamp":1790712569419,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T00:00:00Z","timestamp":1249430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00228-009-0709-5","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T06:15:52Z","timestamp":1249366552000},"page":"941-946","source":"Crossref","is-referenced-by-count":55,"title":["Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET"],"prefix":"10.1007","volume":"65","author":[{"given":"Martin","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Karch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman","family":"Abrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia C.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Kletter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,5]]},"reference":[{"key":"709_CR1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pneurobio.2005.04.006","volume":"76","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22\u201376","journal-title":"Prog Neurobiol"},{"key":"709_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.jcbfm.9600349","volume":"27","author":"M Lubberink","year":"2007","unstructured":"Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA (2007) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[(11)C]verapamil and PET. J Cereb Blood Flow Metab 27:424\u2013433","journal-title":"J Cereb Blood Flow Metab"},{"key":"709_CR3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2967\/jnumed.108.051235","volume":"49","author":"JP Bankstahl","year":"2008","unstructured":"Bankstahl JP, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T, Wadsak W, Kletter K, M\u00fcller M, L\u00f6scher W, Langer O (2008) Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med 49:1328\u20131335","journal-title":"J Nucl Med"},{"key":"709_CR4","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, Leenders KL (2008) Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging. doi: 10.1016\/j.neurobiolaging.2008.02.002","journal-title":"Neurobiol Aging"},{"key":"709_CR5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clpt.2006.02.004","volume":"79","author":"R Toornvliet","year":"2006","unstructured":"Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79:540\u2013548","journal-title":"Clin Pharmacol Ther"},{"key":"709_CR6","doi-asserted-by":"crossref","first-page":"T95","DOI":"10.1016\/j.jalz.2008.05.169","volume":"4","author":"BN Berckel van","year":"2008","unstructured":"van Berckel BN, Lubberink M, Luurtsema G, Boellaard R, Lammertsma AA (2008) Regional variations in age dependence of P-gp mediated transport across the blood-brain barrier measured using (R)-[11C]verapamil and positron emission tomography [symposium abstract]. Alzheimers Dement 4:T95","journal-title":"Alzheimers Dement"},{"key":"709_CR7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","volume":"115","author":"AL Bartels","year":"2008","unstructured":"Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, van Oostrom JC, Portman A, Leenders KL (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 115:1001\u20131009","journal-title":"J Neural Transm"},{"key":"709_CR8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1528-1167.2007.01116.x","volume":"48","author":"O Langer","year":"2007","unstructured":"Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, M\u00fcller M, Baumgartner C (2007) Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil. Epilepsia 48:1774\u20131784","journal-title":"Epilepsia"},{"key":"709_CR9","author":"OL Klerk de","year":"2009","unstructured":"de Klerk OL, Willemsen AT, Roosink M, Bartels AL, Harry Hendrikse N, Bosker FJ, den Boer JA (2009) Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol. doi: 10.1017\/S1461145709009894","journal-title":"Int J Neuropsychopharmacol"},{"key":"709_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS (2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19:224\u2013247","journal-title":"Hum Brain Mapp"},{"key":"709_CR11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clpt.2005.04.011","volume":"78","author":"M Brunner","year":"2005","unstructured":"Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, M\u00fcller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, M\u00fcller M (2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther 78:182\u2013190","journal-title":"Clin Pharmacol Ther"},{"key":"709_CR12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00259-007-0556-5","volume":"35","author":"A Abrahim","year":"2008","unstructured":"Abrahim A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraia E, Joukhadar C, Kletter K, Lammertsma AA, Baumgartner C, M\u00fcller M, Langer O (2008) Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging 35:116\u2013123","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"709_CR13","author":"R Hurlemann","year":"2009","unstructured":"Hurlemann R, Schlaepfer TE, Matusch A, Reich H, Shah NJ, Zilles K, Maier W, Bauer A (2009) Reduced 5-HT2A receptor signaling following selective bilateral amygdala damage. Soc Cogn Affect Neurosci. doi: 10.1093\/scan\/nsn039","journal-title":"Soc Cogn Affect Neurosci"},{"key":"709_CR14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2967\/jnumed.108.050716","volume":"49","author":"AG Mukhin","year":"2008","unstructured":"Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA (2008) Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2\u201318F-FA-85380. J Nucl Med 49:1628\u20131635","journal-title":"J Nucl Med"},{"key":"709_CR15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1984.tb02371.x","volume":"17","author":"M Eichelbaum","year":"1984","unstructured":"Eichelbaum M, Mikus G, Vogelgesang B (1984) Pharmacokinetics of (+)-, (-)- and (+\/-)-verapamil after intravenous administration. Br J Clin Pharmacol 17:453\u2013458","journal-title":"Br J Clin Pharmacol"},{"key":"709_CR16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1023\/A:1010984110732","volume":"18","author":"C Dagenais","year":"2001","unstructured":"Dagenais C, Zong J, Ducharme J, Pollack GM (2001) Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18:957\u2013963","journal-title":"Pharm Res"},{"key":"709_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2967\/jnumed.108.056226","volume":"50","author":"JS Liow","year":"2009","unstructured":"Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding RL, Taku A, Herscovitch P, Pike VW, Innis RB (2009) P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 50:108\u2013115","journal-title":"J Nucl Med"},{"key":"709_CR18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s11095-006-9780-0","volume":"23","author":"S Syv\u00e4nen","year":"2006","unstructured":"Syv\u00e4nen S, Xie R, Sahin S, Hammarlund-Udenaes M (2006) Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res 23:705\u2013717","journal-title":"Pharm Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0709-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0709-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:52:01Z","timestamp":1558687921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0709-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0709-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,5]]}}}